For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

This Siklos Patient Guide contains important information about your treatment, or your child's treatment including advice on preparation and administration of your medicine, disease symptoms, and side effects.

This Physician Guide for Siklos contains important recommendations for patient monitoring, dosage adjustments, and the management of serious adverse effects.

Dosing sheet for physicians to illustrate and record patient's individual daily dosage requirements.

This Patient Reminder Card contains important safety information that you need to be aware of before and during treatment with Simponi

Important risk minimisation information for Patients:

How to take Sodium oxybate 500 mg/ml oral solution Brochure

Important risk minimisation information for Patients and Caregivers:

Sodium oxybate 500 mg/ml oral solution

Frequently Asked Questions (FAQ)

Safety information card for patients, physicians and pharmacists

Important risk minimisation information for Healthcare Professionals:

Sodium oxybate 500 mg/ml oral solution Treatment Initiation and Follow-Up Visit Form

GUIDE FOR PAEDIATRIC PATIENTS AND THEIR CAREGIVERS

IMPORTANT INFORMATION ABOUT SAFE USE AND HANDLING OF SODIUM OXYBATE

In this guide the patient is warned about the risks (of respiratory and central nervous system depression, depression, suicide, seizures, abuse, misuse, illicit and criminal use, overdose, dependence/addiction and the interaction of the product with alcohol and the resulting psychosis) and is told how to proceed in the event of experiencing them.

Guidance for paediatric patients and their caregivers - Important information about safe use and handling of Sodium Oxybate 500 mg/ml oral solution (sodium oxybate).

IMPORTANT RISK MINIMISATION INFORMATION FOR PATIENTS:

How to take SODIUM OXYBATE 500mg/ml Oral solution

This treatment initiation form should be completed by Healthcare Professionals as it is essential to ensure the safe and effective use of Sodium Oxybate 500 mg/ml oral solution and the appropriate management of the important risks. All sections of this form need to be completed, signed and dated and retained in the patient's medical records.

This guide contains recommendations to minimise the risks of respiratory and central nervous system depression, depression, suicide, seizures, abuse, misuse, illicit and criminal use, overdose, dependence/addiction and the interaction of the product with alcohol and the resulting psychosis.

This guide contains recommendations to avoid the risks (respiratory and central nervous system depression, depression, suicide, seizures, abuse, misuse, illicit and criminal use, overdose, dependence/addiction and the interaction of the product with alcohol and the resulting psychosis) and patients are advised to carry this with them at all times.

GUIDE AND CHECKLIST FOR HEALTHCARE PROFESSIONALS Avoiding medication errors with SULIQUA (insulin glargine 100 units/ml + lixisenatide) — available in 2 pre-filled pens containing different dosage strengths.

This card is provided only as a guide to avoid medication errors. Before using Suliqua®, you must be trained on how to use the Suliqua SoloStar® pen by your doctor, nurse or pharmacist, and you must carefully read the patient leaflet and the instructions for use accompanying the pen

PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Checklist for prescribers

PFIZER CHC Norethisterone or Levonorgestrel VTE and ATE RMM Patient card

This is for healthcare professionals to provide to male patients taking valproate as well as their families and caregivers.

Valproate (Blevo, Convulex, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): review by two specialists is required for initiating valproate but not for male patients already taking valproate.

Risk minimisation measures required for Valproate prescribing - This is for the patient 55 years old or over

Risk minimisation measures required for Valproate prescribing - This is for the female patients less than 55 years old.

Risk minimisation measures required for Valproate prescribing - This is for the male patients less than 55 years old.

This information does not replace the overall discussion on risks and benefits which would lead to an informed prescribing decision.